Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectability of pancreatic head cancer with contrasted-enhanced MDCT and its various post processing techniques, taking operational and pathological records as the gold standard.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adenocarcinoma of Head of Pancreas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with (or suspected) pancreatic head cancer
* Being examined by contrasted-enhanced MDCT
* Receiving surgical treatment (including palliative surgery) in all research centers

Exclusion Criteria

* Patients having (or suspected) pregnancy or breast-feeding
* Patients having allergic reactions to iodinated contrast agents or Hypersensitivity reactions to allergens(including drugs)
* Patients receiving ERCP before contrasted-enhanced MDCT examination
* Patients without surgery because of a high degree of surgical risk

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Meng Su Zeng

Mengsu Zeng, MD & Ph.D,Chairman & Professor,Department of Radiology

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mengsu Zeng, MD, PhD

Role: STUDY_CHAIR

Radiology Department, Zhongshan Hospital of Fudan University

Jianping Lu, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Radiology Department, Changhai Hospital Affiliated to Second Military Medical University

Weijun Peng, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Radiology Department, Cancer Hospital Affiliated to Fudan University

Fuhua Yan, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Radiology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University, China

Xiaoyuan Feng, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Radiology Department, Huashan Hospital, Fudan University, China

Yanqing Hua, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Radiology Department, Huadong Hospital Affiliated to Fudan University, China

Locations

Explore where the study is taking place and check the recruitment status at each participating site.